Skip to content

CytomX Therapeutics CTMX Book value per share

Book value per share at other companies

Pfizer logo
PfizerPFE
$15.72-0.6%
Amgen logo
AmgenAMGN
$16.89+47.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
$15.02-8.3%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$1.16-35.1%
Vor Biopharma logo
Vor BiopharmaVOR
-$3.50-133%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$3.55-11.6%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's book value per share?
CytomX Therapeutics (CTMX) reported book value per share of $1.80 in Q1 2026.
How has CytomX Therapeutics's book value per share changed year-over-year?
CytomX Therapeutics's book value per share increased by 528.0% year-over-year, from $0.29 to $1.80.
What is the long-term trend for CytomX Therapeutics's book value per share?
Over 5 years (2020 to 2025), CytomX Therapeutics's book value per share has grown at a 33.9% compound annual growth rate (CAGR), from -$0.17 to $0.72.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.